Harnessing AI-guided visual biology to discover drug targets for neurodegenerative disease
Thursday, April 10 at 07:30 EDT / 12:30 BST / 13:30 CEST / 19:30 CST / 20:30 JST / 21:00 ACST
Advances in visual biology now enable neurodegenerative drug researchers to better visualize and understand complex biological processes. This powerful approach helps to locate new targets and develop therapeutic solutions for diseases that have limited treatment options.
A new visual approach is now possible with the Lightning.AI™ TechBio platform from Anima Biotech. By applying bit.bio’s deterministically programmed cells, this AI-guided platform can run millions of visualizations and image cellular pathways in defined, consistent, and physiologically relevant iPSC-derived cells – both healthy and diseased. This enables the identification of novel drug targets and complex biological pathways.
Join Senior Research Scientist, Dr. Ben Bar-Sadeh from Anima Biotech and Tom Brown, Senior Product Manager at bit.bio, as they share data-driven insights into the latest data on ioMotor Neurons and upcoming ioCells innovations. This collective work exhibits how proprietary deep data can accelerate novel target and drug discovery in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS).
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
Speakers
Who should attend?
- CROs, biotech, and pharma scientists who are involved in preclinical drug discovery for ALS.
What will this webinar cover?
- Understand how bit.bio’s opti-ox deterministic cell programming technology is changing the paradigm of iPSC-derived cells by driving the development of defined, consistent functional human iPSC-derived cells like ioMotor Neurons.
- Gain insights into how Anima Biotech's proprietary deep data generated from human iPSC-derived ioMotor Neurons has identified key dysregulated pathways and novel drug targets for ALS.
- Discover how opti-ox powered ioMotor Neurons can provide a clump-free, reproducible solution for standard assays, including electrophysiology and high-content imaging.
